paliperidone palmitate
Drug Details
- Generic Name
- paliperidone palmitate
- Brand Names
- INVEGA SUSTENNA, Erzofri extended-release, INVEGA HAFYERA, INVEGA TRINZA
- Application Number
- NDA022264
- Sponsor
- Janssen Pharmaceuticals, Inc.
- NDC Codes
- 17
- Dosage Forms
- INJECTION, INJECTION, SUSPENSION, EXTENDED RELEASE
- Routes
- INTRAMUSCULAR
- Active Ingredients
- PALIPERIDONE PALMITATE
Indications and Usage
1 INDICATIONS AND USAGE INVEGA HAFYERA, an every-six-month injection, is indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months, or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. INVEGA HAFYERA, an every-six-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. ( 1 )